Varian, Inc. Reports Fourth Quarter 20...(--------- --------- Total opera...),Health

Date:11/4/2009

--------- --------- Total operating expenses 78,092 93,234 --------- --------- Operating earnings 5,104 (4) 32,859 (11) Interest income 375 1,042 Interest expense (395) (382) --------- --------- Earnings before income taxes 5,084 33,519 Income tax expense 3,144 (5) 13,142 (12) --------- --------- Net earnings $ 1,940 (6) $ 20,377 (13) ========= ========= Net earnings per diluted share $0.07 (6) $0.69 (13) ========= ========= Diluted shares outstanding 29,138 29,367 ========= ========= NON-GAAP (ADJUSTED) FINANCIAL MEASURES (see also attached reconciliations of GAAP to Adjusted results for each of these measures): (1) $111,263 on an adjusted basis excluding $1,550 in acquisition-related intangible amortization, $72 in acquisition-related inventory write-up amortization and $378 in restructuring and other related costs. (2) $55,063 on an adjusted basis excluding $9,155 in costs related to the pending acquisition by Agilent, $194 in acquisition-related intangible amortization and $232 in restructuring and other related costs. (3) $13,694 on an adjusted basis excluding a credit of $246 in restructuring and other related costs. (4) $16,439 on an adjusted basis excluding the adjustments described in
'/>"/>

SOURCE Varian, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results